Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide (REPAMET 2)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: metformin; Drug: repaglinide

Study type: Observational

Funder types: Industry

Identifiers

NCT00745433

AGEE-3558

Details and patient eligibility

About

This study is conducted in Europe. The aim of this observational study is to investigate the efficacy (e.g. glycemic control) and safety (e.g. hypoglycemic episodes) when adding repaglinide to a monotherapy of metformin in type 2 diabetic patients under normal clinical practice

Enrollment: 906 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes
• Metformin monotreatment
• HbA1c greater than 7%
• Treatment according to SPC
• Informed consent obtained

Exclusion criteria

• Any contraindication to the use of repaglinide (according to the SPC)

Trial design

906 participants in 1 patient group

A

Description:

Repaglinide add-on to metformin.

Treatment:

Drug: repaglinide

Drug: metformin